Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Buserelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 2/20 | 0.80 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.79 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.74 |
| ▸ | APLNR | P35414 | 4/20 | 0.61 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Buserelin SCHEMBL15214196 | 1.00 | GNRHR (0.80) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Buserelin SCHEMBL29394496 | 0.99 | ABCC2 (0.81) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Buserelin SCHEMBL3467577 | 0.97 | GNRHR (0.75) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Goserelin SCHEMBL29405686 | 0.96 | GNRHR (0.73) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Goserelin SCHEMBL20459194 | 0.96 | GNRHR (0.73) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Buserelin SCHEMBL2544038 | 0.96 | ABCC2 (0.76) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL4585 | 0.96 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Deslorelin SCHEMBL1649660 | 0.96 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL10061885 | 0.96 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL7751433 | 0.96 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851492-B2 | Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases | MERCK PATENT GMBH (DE) | 2023-12-26 | — | — | US | claimed |
| US-20220275094-A1 | Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases | MERCK PATENT GMBH (DE) | 2022-09-01 | — | — | US | claimed |
| US-11306146-B2 | Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases | MERCK PATENT GMBH (DE) | 2022-04-19 | — | — | US | claimed |
| EP-3746074-B1 | COMPOSITION VÉTÉRINAIRE À BASE DE CABERGOLINE UTILISÉE POUR RÉDUIRE LE RETARD DES CHALEURS CHEZ LES TRUIES | CEVA SANTE ANIMALE (FR) | 2026-05-20 | — | — | EP | disclosed |
| EP-4647095-B1 | ELECTRONIC ADD-ON MODULE AND ASSEMBLY OF AN ELECTRONIC ADD-ON MODULE AND A DRUG DELIVERY DEVICE | SANOFI SA (FR) | 2026-05-06 | — | — | EP | disclosed |
| US-20260103473-A1 | CITRATE SALT OF CYCLIN-DEPENDENT KINASE (CDK4/6) INHIBITOR, CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | AVANC PHARMACEUTICAL CO LTD (CN) | 2026-04-16 | — | — | US | disclosed |
| EP-4434588-B1 | AEROSOL DELIVERY DEVICE | PARI PHARMA GMBH (DE) | 2026-04-08 | — | — | EP | disclosed |
| WO-2025233436-A1 | ELECTRONIC ADD-ON MODULE AND ASSEMBLY OF AN ELECTRONIC ADD-ON MODULE AND A DRUG DELIVERY DEVICE | SANOFI (FR) | 2025-11-13 | — | — | WO | disclosed |
| EP-4647095-A1 | ELECTRONIC ADD-ON MODULE AND ASSEMBLY OF AN ELECTRONIC ADD-ON MODULE AND A DRUG DELIVERY DEVICE | Sanofi (FR) | 2025-11-12 | — | — | EP | disclosed |
| WO-2025217590-A1 | COMPOSITIONS AND METHODS OF MAKING POLYMERIC NANOPARTICLES FOR DELIVERY OF THERAPEUTIC AGENTS | ENVOYA, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-4594351-A1 | GLYCAN-MEDIATED PROTEIN DEGRADATION | GlycoEra AG (CH) | 2025-08-06 | — | — | EP | disclosed |
| US-20220275094-A1 | Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases | MERCK PATENT GMBH (DE) | 2022-09-01 | — | — | US | disclosed |
| WO-2022178203-A1 | ANTI-VISTA ANTIBODIES AND USES THEREOF | Kineta, Inc. (US) | 2022-08-25 | — | — | WO | disclosed |
| US-11415581-B2 | Method of treating solid cancers and/or metastases thereof with pan AV integrin inhibitor, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof | MERCK PATENT GMBH (DE) | 2022-08-16 | — | — | US | disclosed |
| CN-110709120-B | Auto-injector storage device | 赛诺菲-安万特德国有限公司 | 2022-06-28 | — | — | CN | disclosed |
| WO-2022122899-A1 | COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION | FERRING B.V. (NL) | 2022-06-16 | — | — | WO | disclosed |
| US-11351228-B2 | Methods of treating infertility | FERRING B.V. (NL) | 2022-06-07 | — | — | US | disclosed |
| CN-109475695-B | Injection needle assembly | 赛诺菲-安万特德国有限公司 | 2022-05-06 | — | — | CN | disclosed |
| US-11306146-B2 | Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases | MERCK PATENT GMBH (DE) | 2022-04-19 | — | — | US | disclosed |
| CN-108495666-B | Medicament injection device | 赛诺菲-安万特德国有限公司 | 2022-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103473-A1 | CITRATE SALT OF CYCLIN-DEPENDENT KINASE (CDK4/6) INHIBITOR, CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | CDK4, CDK1, CDK6 | GNRHR 972/4885ABCC2 3422/4885PTGS1 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.